RLMD - Relmada Therapeutics: A Promising Depression Focused Player For 2020
Today, we will study why Relmada Therapeutics (RLMD) is an attractive clinical-stage biopharmaceutical pick in 2020.
Company overview
Relmada Therapeutics is a clinical-stage biotechnology company focused on advancing REL-1017 (d-methadone or dextromethadone) as a rapid-acting oral treatment option for depression and other CNS (central nervous system) disorders. The company's lead asset, REL-1017 is a non-competitive NMDA (N-methyl-D-aspartate) receptor, antagonist. Besides depression, the company also plans to study REL-1017 in other indications such as Rett Syndrome, ophthalmological conditions, and mitochondrial diseases.
Relmada Therapeutics' research pipeline also comprises of investigational assets such as REL-1015 (LevoCap ER) which